150 related articles for article (PubMed ID: 35018845)
21. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Palumbo A; Chanan-Khan A; Weisel K; Nooka AK; Masszi T; Beksac M; Spicka I; Hungria V; Munder M; Mateos MV; Mark TM; Qi M; Schecter J; Amin H; Qin X; Deraedt W; Ahmadi T; Spencer A; Sonneveld P;
N Engl J Med; 2016 Aug; 375(8):754-66. PubMed ID: 27557302
[TBL] [Abstract][Full Text] [Related]
22. Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
Blair HA
Drugs; 2017 Dec; 77(18):2013-2024. PubMed ID: 29127588
[TBL] [Abstract][Full Text] [Related]
23. EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
Tzogani K; Penninga E; Schougaard Christiansen ML; Hovgaard D; Sarac SB; Camarero Jimenez J; Garcia I; Lafuente M; Sancho-López A; Salmonson T; Gisselbrecht C; Pignatti F
Oncologist; 2018 May; 23(5):594-602. PubMed ID: 29371479
[TBL] [Abstract][Full Text] [Related]
24. Asthma rescue and allergy medication use among asthmatic children with prior allergy prescriptions who initiated asthma controller therapy.
Luskin A; Bukstein D; Kocevar VS; Yin DD
Ann Allergy Asthma Immunol; 2005 Aug; 95(2):129-36. PubMed ID: 16136761
[TBL] [Abstract][Full Text] [Related]
25. Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma.
Shibayama H; Matsumoto M; Kosugi H; Shibayama K; Yamazaki H; Iida S
Int J Hematol; 2021 Jan; 113(1):112-121. PubMed ID: 32915384
[TBL] [Abstract][Full Text] [Related]
26. Impact of Premedication De-Escalation on Incidence of Infusion-Related Reactions With Daratumumab.
Vazirnia D; Del Rio Verduzco A; Soefje SA; Sanders KA; Sandahl TB
JCO Oncol Pract; 2024 Feb; ():OP2300470. PubMed ID: 38408288
[TBL] [Abstract][Full Text] [Related]
27. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
Lokhorst HM; Plesner T; Laubach JP; Nahi H; Gimsing P; Hansson M; Minnema MC; Lassen U; Krejcik J; Palumbo A; van de Donk NW; Ahmadi T; Khan I; Uhlar CM; Wang J; Sasser AK; Losic N; Lisby S; Basse L; Brun N; Richardson PG
N Engl J Med; 2015 Sep; 373(13):1207-19. PubMed ID: 26308596
[TBL] [Abstract][Full Text] [Related]
28. Daratumumab for the treatment of multiple myeloma.
Touzeau C; Moreau P
Expert Opin Biol Ther; 2017 Jul; 17(7):887-893. PubMed ID: 28434255
[TBL] [Abstract][Full Text] [Related]
29. Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study.
Takamatsu H; Iida S; Shibayama H; Shibayama K; Yamazaki H; Suzuki K
Int J Hematol; 2020 May; 111(5):692-701. PubMed ID: 32002821
[TBL] [Abstract][Full Text] [Related]
30. [Daratumumab - Hope for Myeloma Patients, a Challenge for Clinical Laboratories].
Jelínek T; Kořístka M; Čermáková Z; Hájek R
Klin Onkol; 2017; 30(1):13-19. PubMed ID: 28185460
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Afifi S; Michael A; Lesokhin A
Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of montelukast in adults with asthma and allergic rhinitis.
Virchow JC; Bachert C
Respir Med; 2006 Nov; 100(11):1952-9. PubMed ID: 16626955
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of a Pharmacist-Developed, Nurse-Driven Protocol for Management of Parenteral Anticancer Therapy Infusion Reactions in an Ambulatory Infusion Center.
Cebollero J; LaFollette JA; Walton SM; Adams Curry M
J Oncol Pharm Pract; 2023 Jun; 29(4):802-809. PubMed ID: 35164607
[TBL] [Abstract][Full Text] [Related]
34. Asthma control in patients with asthma and allergic rhinitis receiving add-on montelukast therapy for 12 months: a retrospective observational study.
Borderias L; Mincewicz G; Paggiaro PL; Guilera M; Sazonov Kocevar V; Taylor SD; Badia X
Curr Med Res Opin; 2007 Apr; 23(4):721-30. PubMed ID: 17407628
[TBL] [Abstract][Full Text] [Related]
35. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
[TBL] [Abstract][Full Text] [Related]
36. Daratumumab Split First Versus Single Dosing Schedule Among Patients With Multiple Myeloma Treated in a US Community Oncology Setting: A Retrospective Observational Study.
Rifkin R; Singer D; Aguilar KM; Baidoo B; Maiese EM
Clin Ther; 2019 May; 41(5):866-881.e7. PubMed ID: 31030993
[TBL] [Abstract][Full Text] [Related]
37. [The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma].
Jia YJ; Liu H; Wang LR; Wang T; Feng R; Chen YJ; Wang M; Guo HX; Wen L; Duan WB; Yang YZ; Wang FR; Chen YY; Huang XJ; Lu J
Zhonghua Nei Ke Za Zhi; 2020 May; 59(5):347-352. PubMed ID: 32370462
[No Abstract] [Full Text] [Related]
38. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
[No Abstract] [Full Text] [Related]
39. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos MA; Oriol A; Nahi H; San-Miguel J; Bahlis NJ; Usmani SZ; Rabin N; Orlowski RZ; Komarnicki M; Suzuki K; Plesner T; Yoon SS; Ben Yehuda D; Richardson PG; Goldschmidt H; Reece D; Lisby S; Khokhar NZ; O'Rourke L; Chiu C; Qin X; Guckert M; Ahmadi T; Moreau P;
N Engl J Med; 2016 Oct; 375(14):1319-1331. PubMed ID: 27705267
[TBL] [Abstract][Full Text] [Related]
40. Daratumumab in multiple myeloma.
Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]